This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
by Zacks Equity Research
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Cardinal Health (CAH) Stock Moves -1.2%: What You Should Know
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $128.88, representing a -1.2% change from its previous close.
Align Technology (ALGN) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Align Technology (ALGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
by Zacks Equity Research
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Is it the Right Time to Add EYE Stock to Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts. Positive industry trends should also favor its growth.
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
by Zacks Equity Research
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
by Zacks Equity Research
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
ZBH Stock to Gain From Volume Growth Amid Rising Costs
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
GMED Stock May Benefit Following the Acquisition of Nevro
by Zacks Equity Research
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back acquisitions & partnerships. A tough regulatory environment raises concerns.
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
by Zacks Equity Research
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Reasons to Add ABT Stock to Your Portfolio Right Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.
RMD Stock Benefits From the Launch of NightOwl Across US
by Zacks Equity Research
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
Cardinal Health (CAH) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
The latest trading day saw Cardinal Health (CAH) settling at $137.09, representing a -1.14% change from its previous close.
Global Expansion in EPD and Innovations Support Abbott Stock
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bruker Introduces Breakthrough d-DNP Polarizer: Stock to Gain?
by Zacks Equity Research
BRKR announces first successful customer installation of novel d-DNP Polarizer at UCSF.
Trump's Retaliatory Tariffs Threaten Markets: 5 Low-Beta Stocks to Buy
by Ritujay Ghosh
Investing in defensive stocks like SWX, CMS, TAP, SONY and CAH is a safe bet during times of market volatility.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
ALC Stock May Rise With the Introduction of PanOptix Pro in US
by Zacks Equity Research
Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.
VEEV Stock Slips Despite New Research Site Clinical Trial System
by Zacks Equity Research
Veeva introduces a Research Site Clinical Trial Management System to streamline trial operations, enhance collaboration, and accelerate clinical research efficiency.